Crinetics Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumors and ...
Discover Boehringer Ingelheim’s pipeline focus areas and how its dealmaking in 2025 has expanded its therapeutic arsenal.
As bispecifics, ADCs, protein degraders, and AI-designed mini-proteins move into the clinic, discovery teams face a new ...
Pharmaceuticals announced the first patient has been dosed in the Phase 1/2 study evaluating CRN09682 in patients with metastatic ...
The Tectonic management team will host one-on-one meetings during the two conferences. Interested investors should contact their Piper Sandler and Evercore representatives to schedule meetings.
The main market opportunities for CCR8-targeted immunotherapies lie in its potential to address unmet needs in cancer treatment by selectively depleting immunosuppressive Tregs in tumors, enhancing ...
Una nueva molécula podría desempeñar un papel importante en el desarrollo y la función de las células T RM, según el ...
If you’re looking for investment ideas right now, several top-rated Wall Street analysts (each with five-star ratings) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback